Get the Stockscreener App
0.2791
3.60%
-0.0115
IGC Pharma Inc stock is traded at $0.2791, with a volume of 53,521.
It is down -3.60% in the last 24 hours and down -16.32% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.2906
Open:
$0.2919
24h Volume:
53,521
Relative Volume:
0.16
Market Cap:
$19.24M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.0735
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
+1.14%
1M Performance:
-16.32%
6M Performance:
-31.17%
1Y Performance:
-42.36%
1-Day Range:
$0.2779
$0.2919
1-Week Range:
$0.2659
$0.2919
52-Week Range:
$0.2525
$0.65
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2791 | 19.24M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.97 | 126.49B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.14 | 59.71B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.24 | 36.26B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.99 | 29.48B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.50 | 25.29B | 3.81B | -644.79M | -669.77M | -6.24 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma expands CALMA trial with addition of Butler Hospital Program - Yahoo Finance
IGC Pharma Expands Phase 2 Alzheimer's Trial Site - MarketScreener
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - ACCESS Newswire
Major Breakthrough: IGC's Alzheimer's Agitation Drug Trial Adds Prestigious Brown University Research Site - Stock Titan
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - PharmiWeb.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addi - GuruFocus
IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health - TipRanks
IGC Pharma expands CALMA clinical trial - TipRanks
IGC Pharma posts promising interim data for Alzheimer’s therapy - MSN
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances - BioSpace
Breakthrough: New Alzheimer's Drug Cuts Sleep Disturbances by 78% in Phase 2 Trial - Stock Titan
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction In Sleep Disturbances - Barchart.com
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial - Clinical Trials Arena
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences - BioSpace
IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy - MarketScreener
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida - ACCESS Newswire
IGC Pharma's Alzheimer's Drug Shows Promise: CALMA Trial Adds New Florida Site - StockTitan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" - ACCESS Newswire
IGC Pharma Catches Analyst Attention: $4.25 Target Set as Clinical Milestones Approach - StockTitan
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" - ACCESS Newswire
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results” | FinancialContent - Financial Content
IGC Pharma's Alzheimer's Drug Trial Gets Positive Analyst Coverage - Stock Titan
IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer’s Diagnosis - Insider Monkey
12 AI Stocks Making Headlines: Latest News and Ratings - Insider Monkey
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection - Big News Network
Can This New AI Tool Revolutionize How Doctors Diagnose Alzheimer's Disease? - StockTitan
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’ - Yahoo Finance
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and - GuruFocus.com
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew'Targeting the Multi-Billion-Dollar Anti-Aging Market - Newswire
IGC Pharma's Earnings Show Major Turnaround: Net Loss Shrinks 69% While Alzheimer's Drug Shows Promise - StockTitan
IGC Pharma Reports Third Quarter Fiscal 2025 Results - ACCESS Newswire
IGC Pharma Inc. (IGC) reports earnings - Quartz
Page 3 | IGC PHARMA INC. DL -,01 Trade Ideas — FWB:IGS1 - TradingView
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) - StreetInsider.com
IGC Pharma launches Holiby wellness brand - TipRanks
IGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby - finanznachrichten.de
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
2.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):